Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Denali Therapeutics (DNLI) Tax Provisions (2019 - 2023)

Denali Therapeutics (DNLI) has disclosed Tax Provisions for 5 consecutive years, with $30000.0 as the latest value for Q4 2023.

  • On a quarterly basis, Tax Provisions rose 600.0% to $30000.0 in Q4 2023 year-over-year; TTM through Dec 2023 was $24000.0, a 104.33% increase, with the full-year FY2025 number at $102000.0, up 50.0% from a year prior.
  • Tax Provisions was $30000.0 for Q4 2023 at Denali Therapeutics, up from -$6000.0 in the prior quarter.
  • In the past five years, Tax Provisions ranged from a high of $788000.0 in Q4 2020 to a low of -$575000.0 in Q4 2021.
  • A 5-year average of -$4727.3 and a median of $27000.0 in 2022 define the central range for Tax Provisions.
  • Peak YoY movement for Tax Provisions: soared 950.67% in 2020, then tumbled 172.97% in 2021.
  • Denali Therapeutics' Tax Provisions stood at $75000.0 in 2019, then skyrocketed by 950.67% to $788000.0 in 2020, then crashed by 172.97% to -$575000.0 in 2021, then soared by 98.96% to -$6000.0 in 2022, then surged by 600.0% to $30000.0 in 2023.
  • Per Business Quant, the three most recent readings for DNLI's Tax Provisions are $30000.0 (Q4 2023), -$6000.0 (Q4 2022), and $27000.0 (Q2 2022).